Morin attenuates hepatic insulin resistance in high-fat-diet-induced obese mice

J Physiol Biochem. 2016 Jun;72(2):269-80. doi: 10.1007/s13105-016-0477-5. Epub 2016 Mar 14.

Abstract

Morin is a natural bioflavonoid that exhibits antioxidant and anti-inflammatory properties. The present study was designed to evaluate the effect of morin on insulin resistance, oxidative stress, and inflammation in a high-fat-diet (HFD)-induced obese mice. Obesity was induced in ICR mice by feeding a HFD (60 % kcal from fat) for 12 weeks. After the first 6 weeks, obese mice were treated with morin (50 or 100 mg/kg/day) once daily for further 6 weeks. Blood glucose, lipid profile, insulin, leptin, adiponectin, and markers of oxidative stress and inflammation were then measured. Liver was excised, subjected to histopathology, glycogen determination, and gene and protein expression analysis. Morin administration reduced blood glucose, serum insulin, leptin, malondialdehyde, interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) levels and increased serum adiponectin levels. Moreover, there was a reduction in serum lipid and liver triglyceride levels. Liver histology indicated that morin limited accumulation of lipid droplets. Interestingly, morin reduced expression of hepatic sterol regulatory element binding protein 1c (SREBP1c), fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) and up-regulated hepatic carnitine palmitoyltransferase 1a (CPT1a) expression. Morin also stimulated glycogen storage and suppressed phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) protein expression. Furthermore, hepatic superoxide dismutase (SOD) and catalase (CAT) expression were increased after morin treatment. These findings indicate that morin has a positive effect in the HFD-induced obesity condition by suppressing lipogenesis, gluconeogenesis, inflammation, and oxidative stress activities.

Keywords: Inflammation; Insulin resistance; Morin; Obesity; Oxidative stress.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Anti-Obesity Agents / administration & dosage
  • Antioxidants / administration & dosage
  • Antioxidants / therapeutic use*
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Diet, High-Fat / adverse effects
  • Dose-Response Relationship, Drug
  • Flavonoids / administration & dosage
  • Flavonoids / therapeutic use*
  • Gene Expression Regulation / drug effects
  • Gluconeogenesis / drug effects
  • Hyperglycemia / etiology
  • Hyperglycemia / prevention & control
  • Hyperinsulinism / etiology
  • Hyperinsulinism / prevention & control
  • Hyperlipidemias / etiology
  • Hyperlipidemias / prevention & control
  • Insulin Resistance*
  • Lipid Peroxidation / drug effects
  • Lipogenesis / drug effects
  • Liver / drug effects*
  • Liver / immunology
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Mice, Inbred ICR
  • Obesity / drug therapy*
  • Obesity / immunology
  • Obesity / metabolism
  • Obesity / pathology
  • Oxidative Stress / drug effects
  • Weight Gain / drug effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anti-Obesity Agents
  • Antioxidants
  • Biomarkers
  • Flavonoids
  • morin